NEW YORK, Sept. 14, 2011 /PRNewswire/ — Delcath Systems, Inc.
(NASDAQ:
DCTH) today announced that the Company sponsored an industry
symposium at the Cardiovascular and Interventional Radiological
Society of Europe (CIRSE) in Munich, Germany—the largest
international forum for minimally invasive image-guided therapy,
with more than 5,600 interventional radiologists in attendance.
The event, held Tuesday, September 13th, was moderated by Dr.
Riccardo Lencioni—Associate Professor of Radiology and Head
of Diagnostic Imaging and Intervention in the Department of Liver
Transplantation, Hepatology and Infectious Diseases of the
University of Pisa, and featured presentations by three U.S.
physicians with direct experience with chemosaturation from the
Company’s Phase 3 Trial:
Jonathan Zager, MD — Associate Professor of Surgery in the
Cutaneous Oncology and Sarcoma Departments at the Moffitt Cancer
Center – Evolution, Concepts and Utility for Patients with
Liver Cancer James R. Pingpank,MD — Division of Surgical
Oncology at the University of Pittsburgh Medical Center and
Principal Investigator on the phase 3 trial of chemosaturation via
(PHP) device – Summary of Phase 3 Clinical Trial Results
Fred Moeslein, MD —Assistant Professor of Diagnostic
Radiology and Nuclear Medicine at the University of Maryland
Medical Center – Practical Experience with
Chemosaturation
Commenting on the announcement, Eamonn P. Hobbs, President &
CEO of Delcath, said, “This session was an opportunity to present
detailed information on the clinical evidence and conceptual
framework for chemosaturation to a broad audience of EU-based
interventional radiologists. Attendance at the session exceeded the
room’s capacity. We believe this level of
participation—combined with the favorable respon
‘/>”/>
